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Summary
Background Georgia has a high prevalence of hepatitis C, with 5·4% of adults chronically infected. On April 28, 2015, 
Georgia launched a national programme to eliminate hepatitis C by 2020 (90% reduction in prevalence) through 
scaled-up treatment and prevention interventions. We evaluated the interim effect of the programme and feasibility 
of achieving the elimination goal.
Methods We developed a transmission model to capture the hepatitis C epidemic in Georgia, calibrated to data from 
biobehavioural surveys of people who inject drugs (PWID; 1998–2015) and a national survey (2015). We projected the 
effect of the administration of direct-acting antiviral treatments until Feb 28, 2019, and the effect of continuing current 
treatment rates until the end of 2020. Effect was estimated in terms of the relative decrease in hepatitis C incidence, 
prevalence, and mortality relative to 2015 and of the deaths and infections averted compared with a counterfactual of 
no treatment over the study period. We also estimated treatment rates needed to reach Georgia’s elimination target.
Findings From May 1, 2015, to Feb 28, 2019, 54 313 patients were treated, with approximately 1000 patients treated per 
month since mid 2017. Compared with 2015, our model projects that these treatments have reduced the prevalence of 
adult chronic hepatitis C by a median 37% (95% credible interval 30–44), the incidence of chronic hepatitis C by 
37% (29–44), and chronic hepatitis C mortality by 14% (3–30) and have prevented 3516 (1842–6250) new infections 
and averted 252 (134–389) deaths related to chronic hepatitis C. Continuing treatment of 1000 patients per month is 
predicted to reduce prevalence by 51% (42–61) and incidence by 51% (40–62), by the end of 2020. To reach a 
90% reduction by 2020, treatment rates must increase to 4144 (2963–5322) patients initiating treatment per month.
Interpretation Georgia’s hepatitis C elimination programme has achieved substantial treatment scale-up, which has 
reduced the burden of chronic hepatitis C. However, the country is unlikely to meet its 2020 elimination target unless 
treatment scales up considerably.
Funding CDC Foundation, National Institute for Health Research, National Institutes of Health.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the 
CC BY-NC-ND 4.0 license.
Introduction
Hepatitis C virus (HCV) infection causes liver disease,1,2 
with 71 million people being infected globally in 2015 and 
80% of them living in low-income and middle-income 
countries.3 HCV is primarily transmitted by injection 
drug use and unsafe medical procedures.4–6 The develop-
ment of highly curative direct-acting antiviral treatments 
for HCV contributed to WHO’s 2016 global strategy to 
eliminate hepatitis C.7
Hepatitis C prevalence is high in Georgia, with 
150 000 adults (5·4% of the adult population) infected in 
2015.8 Georgia launched the first national hepatitis C 
elimination programme in 2015, with donated treatments 
from Gilead Sciences and technical assistance from the 
US Centers for Disease Control and Prevention.9 This 
programme aims to reduce the prevalence of chronic 
hepatitis C infection by 90% through diagnosing 90% of 
infections, treating 95% of diagnosed infections, and 
curing 95% of treated individuals (90-95-95 target) 
by 2020.
A national survey done in 20158 found considerable 
variation in prevalence of chronic hepatitis C by gender 
and age. The highest prevalence of infection (15·7%) 
was among men aged 30–49 years, with much lower 
prevalence in adult women (2·2%). The high prevalence 
of chronic hepatitis C in men in this age bracket is 
thought to have resulted from extensive transmission 
after the collapse of the Soviet Union in 1991, when civil 
war and economic collapse10 resulted in considerable 
drug trafficking and injection drug use in Georgia.11 
Although injection drug use has decreased since then, 
Georgia still has a high rate of injection drug use (2% of 
adults)12 compared with the global average (0·33%).4 
Iatrogenic HCV transmission also occurred because of 
insufficient infection control practices and inadequately 
screened blood supply, which were not addressed until 
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after 2009.8,13 Prevention of these modes of transmission 
and improvements in harm-reduction interventions for 
people who inject drugs (PWID) are goals of the 
elimination programme, alongside HCV case-finding 
and treatment.14
We estimated the interim effect of the Georgian 
hepatitis C elimination programme using HCV trans-
mission modelling with empirical treatment data and 
evaluated whether treatment needs scaling up to achieve 
the elimination target.
Methods
Model description
We developed a compartmental model of HCV 
transmission related to injection drug use and in the 
general population (iatrogenic and other risk factors) 
incorporating the changing demographics of PWID 
in Georgia (appendix pp 2–6). The model assumes 
susceptible (ie, uninfected) individuals can become 
infected, with some spontaneously clearing their infection 
and the remainder developing life-long chronic infection 
unless treated. Successful treatment leads to a sustained 
virologic response (ie, effective cure), which results in 
individuals becoming susceptible to re-infection. The 
model is stratified by HCV infection status (figure 1A), 
gender, age (figure 1C), liver disease progression 
(figure 1B), and injection drug use status (ie, PWID, 
people who have never injected drugs [non-PWID], and 
people who used to inject drugs; figure 1C).
Individuals enter the model at birth as susceptible non-
PWID and transition through age categories, with some 
starting injection drug use at age-specific and gender-
specific rates to match self-reported ages of initiation of 
injection drug use and proportion of female PWID 
(appendix p 4). Vertical HCV transmission is not included 
because few young women are infected (1%). Mortality of 
PWID is increased, compared with the general 
population, because of drug-related causes and this 
population ceases injecting at age-specific rates.
Susceptible individuals become infected at a rate 
proportional to Georgia’s chronic hepatitis C prevalence, 
with a general transmission rate that applies to the whole 
population and an additional injection drug use-related 
transmission rate. Both transmission rates vary over 
time to account for changes in risk and harm-reduction 
intervention coverage. The model also allows for 
assortative mixing between younger (<30 years) and 
older (≥30 years) PWID.
Individuals with chronic infection progress through 
stages of liver disease (figure 1B). Individuals with 
decompensated cirrhosis and hepatocellular carcinoma 
have a heightened liver-related mortality. Treatment 
rates (ie, the number of individuals that initiate 
treatment per month) vary over time and by liver 
disease stage to match data from the elimination 
programme. Sustained virologic response halts disease 
progression for mild or moderate liver disease, whereas 
it continues at a decreased rate for more progressed 
Research in context
Evidence before this study
We identified mathematical models of hepatitis C elimination by 
searching PubMed from database inception to May 1, 2019, using 
the terms “(“HCV” OR “Hepatitis C”) AND “elimination” AND 
(“model” OR “projection”)” in title and abstract fields. We 
identified several studies that project the scale-up of treatment of 
hepatitis C virus (HCV) infection required to eliminate hepatitis C 
within high-risk populations, such as people who inject drugs 
(PWID) or people living with HIV in subnational regions of the UK, 
Greece, Australia, and the USA, or nationally in Iceland, the USA, 
and Australia. We also identified models of hepatitis C elimination 
among the general population for subnational regions of the USA 
and Austria; at the national level for Switzerland, Australia, Italy, 
Greece, Belgium, Egypt, and Pakistan; regionally for the EU; and 
one global model. Of the national-level studies, only the general 
population models for Egypt and Pakistan, and the PWID-focused 
models in Iceland, Australia, and USA were based on dynamic 
HCV transmission models that account for the prevention impact 
of treatment on HCV incidence. No studies evaluated the interim 
effect of an ongoing HCV elimination programme.
Added value of this study
This study uses a dynamic model of HCV transmission among 
PWID and the general population to assess the interim effect 
of the first national-level HCV elimination programme in 
Georgia, a country with high HCV prevalence (5·4% in 2015). 
This study illustrates the importance of using modelling to 
assess the progress of ongoing elimination programmes. 
It suggests that a substantial effect (37% decrease in 
incidence and prevalence) has already been achieved by the 
Georgian HCV elimination programme, but that treatment 
rates either need to be increased dramatically (by four times) 
or the duration of the programme needs lengthening (from 
2020 to 2026), to ensure it reaches its primary endpoint of a 
90% reduction in HCV prevalence compared with the 
prevalence in 2015.
Implications of all the available evidence
Published data highlight that rapid and substantial treatment 
scale-up is required to reach HCV elimination targets set by 
WHO by 2030. This study shows that countries can achieve 
large increases in treatment, which should achieve substantial 
decreases in prevalence and incidence, but highlights the 
challenges of implementing sufficient scale-up to achieve 
elimination over a short timeframe even with a high level of 
government commitment.
See Online for appendix
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disease.15 Individuals with hepatocellular carcinoma are 
not treated.
Model parameterisation and calibration
The model was parameterised and calibrated to the 
current HCV epidemic in Georgia, as described herein. 
We simulated a stable population approximating current 
demographic trends, within which we initiated injection 
drug use and HCV transmission in 1960. This time 
threshold was selected because individuals infected with 
HCV before this time are unlikely to be alive now and it 
enabled modelled HCV prevalences to reach equilibrium 
before changes in injection drug use were introduced. 
We modelled changes in injection drug use and asso-
ciated HCV over time because evidence suggests it has 
shaped the Georgian HCV epidemic.11
Calibration and validation data
The model was calibrated to data on the prevalence of 
chronic hepatitis C from the 2015 national prevalence 
survey8 and seven biobehavioral surveys of PWID done 
during 1998–2015 (table 1; appendix pp 11).17,18,20–23 The 
model was also calibrated to an observed ageing of PWID 
between 1998 and 2015, thought to be due to reductions 
in initiation of injection drug use (appendix p 14). Model 
projections were validated against empirical unpublished 
data for HCV incidence among PWID in 1997–2001 
(appendix pp 7, 8), chronic hepatitis C prevalence data for 
PWID from five surveys (2001–12), and age-specific 
chronic hepatitis C prevalence data from the 2015 national 
prevalence survey not used for calibration.8,17,18,20–23
Model parameterisation
Disease progression and HCV-related and injection drug 
use-related mortality were obtained from published 
literature,15,24–26 whereas gender-specific and age-specific 
mortality were derived from life tables for Georgia27 
(table 2; appendix pp 9–11). PWID recruitment and 
cessation parameters were estimated by fitting the model 
to the proportion of PWID that were aged 18–29 years and 
30–49 years in 1998 and 2015, the estimated number of 
PWID in 2014, and their gender distribution (table 1; 
appendix p 11). The number of PWID in Georgia is 
thought to have increased dramatically after the fall of 
the Soviet Union, as suggested by an eight-fold increase 
in police records for people who used drugs over 
1990–2004.10,11 However, no PWID population size esti-
mates exist over this time period,10 so we assumed a 
transient peak in the initiation of injection drug use, 
allowing uncertainty in its timing and magnitude (table 2; 
appendix pp 9, 10). The effect of assuming a peak in 
initiation of injecting was tested in our sensitivity 
analyses.
Needle and syringe programmes were initiated in 
Georgia in 2001 and opioid substitution therapy in 2005,29 
with 4·5 million syringe kits distributed and 30 330 PWID 
reached by needle and syringe programmes in 2016, and 
4775 PWID on opioid substitution therapy in the same 
year.20 The efficacy of opioid substitution therapy for 
reducing the risk of HCV acquisition (37–60) among 
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Figure 1: Schematics of state transitions in the model
(A) Infection compartments, (B) liver disease state compartments, (C) PWID and age compartments. Gender 
compartments are not shown. Dotted lines indicate transition to death. ex-PWID=people who used to inject drugs. 
Non-PWID=people who have never injected drugs. PWID=people who inject drugs.
Target value Mean and range across 
baseline model fits
Population of Georgia16 3·72 million 3·73 million (3·35–4·10)
Hepatitis C prevalence in adult population8 5·4% 5·4% (4·5–6·3)
Hepatitis C prevalence in adult women8 2·2% 2·2% (1·6–2·9)
Hepatitis C prevalence in adult men8 9·0% 9·7% (6·7–12·6)
Hepatitis C prevalence among PWID17 51·0% 50·8% (45·4–66·3)
Hepatitis C prevalence in PWID aged 18–24 years17 15·5% 36·1% (14·6–46·7)
Ratio of hepatitis C prevalence in PWID younger 
than 30 years in 1997 vs 201517,18
0·5 0·81 (0·40–1·0)
PWID population size in Georgia,19 in 2014 49 700 83 999 (23 932–190 501)
Proportion of PWID that are female17 2·0% 3·1% (0·1–8·0)
Proportion of PWID <30 years old,18 in 1998 63·2% 62·4% (51·5–72·6)
Proportion of PWID <30 years old17 19·4% 34·6% (20·7–46·0)
Data refer to 2015 unless otherwise specified. References indicate where target values were obtained from. A full list of 
summary statistics is available in the appendix (p 11). Adults are defined as individuals aged 18 years or older. 
PWID=people who inject drugs.
Table 1: Key summary statistics used for calibrating the hepatitis C virus transmission model for Georgia
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PWID was obtained from a Cochrane review.28 Because 
of uncertainty in the efficacy of needle and syringe 
programmes and associated behavioural changes, we 
fitted the population-level effectiveness of needle and 
syringe programmes among PWID to capture an 
observed halving in HCV prevalence among young 
PWID (<30 years) over 1998–2006 (table 2; appendix 
p 15).
The general population HCV transmission rate was also 
allowed to reduce over 1994–2000 to account for reductions 
in medical risks coinciding with restructuring of the 
health system and the introduction of new regulations 
including blood donor screening from 1997.13,14
Model calibration
We used a Markov Chain Monte Carlo Approximate 
Bayesian Computation (MCMC-ABC) approach to 
calibrate the model (appendix p 7).31 The method 
computes a probability distribution of model parameter 
values (the posterior) that constrain the initial prior 
ranges, producing model fits that incorporate uncertainty 
in the model parameters and calibration data. The 
parameter sets identified through MCMC-ABC were then 
filtered to only retain those within 95% CIs of the chronic 
hepatitis C prevalence for all adults (4·5–6·3) and adult 
women (1·6–2·9) from the 2015 national prevalence 
survey8 and for PWID (45·5–56·1) from the 2015 
biobehavioral surveys.17 These filtered runs were termed 
the baseline model fits and were used to estimate the 
median and 95% credible interval (CrI) or central 
95% range of all model projections.
Intervention analyses
We estimated the progress that Georgia has made toward 
its elimination goal by modelling the effect of all direct-
acting antiviral treatments given from May 1, 2015, to 
Feb 28, 2019. The model used monthly treatment 
initiation data for the elimination programme, accounting 
for severity of liver disease and the initial targeting of 
patients with cirrhosis (table 3; appendix p 12).9 Adjusted 
cure rates were used, calculated separately for patients 
with or without cirrhosis. These cure rates assumed the 
per-protocol sustained virologic response rate (table 3) for 
the 78% of patients who completed treatment among 
those who initiated it, and a reduced sustained virologic 
response rate (55%) for the remaining individuals that 
did not complete treatment, based on studies of shorter 
treatment regimens (appendix p 7).32
Effect was estimated in terms of the relative decrease 
in incidence and prevalence from Jan 1, 2015 (with 
treatment given from May 1, 2015), to Feb 28, 2019, and of 
the deaths and infections averted compared with 
a counterfactual of no treatment over this period. The 
future benefits of these treatments were also estimated up 
until 2030, assuming treatment stopped after Feb 28, 2019.
We then estimated the effect of either maintaining the 
current treatment rate (approximately 1000 patients treated 
per month from Aug 1, 2017, to Feb 28, 2019) or scaling-up 
treatment rates to achieve the 90-95-95 treatment target 
set by the Georgian Government (equivalent to treating 
128 250 individuals during 2015–20). Lastly, we estimated 
the treatment rate required from the start of the 
programme and from March 1, 2019, to achieve the 
90% reduction in prevalence set by the Georgian 
elimination target. For each strategy, we also estimated the 
effect on incidence and the number of prevented infections 
and deaths by the end of 2020.
Sensitivity analysis
In our baseline intervention scenarios, we assumed 
that all individuals eligible for treatment were equally 
Prior range* Posterior median (IQR)
Average duration of injecting (years) among PWID aged <29 years 5–50 17·3 (10·9–29·8)
Average duration of injecting (years) among PWID aged 
30–49 years
5–50 38·1 (30·6–44·3)
Average duration of injecting (years) among PWID aged ≥50 years 5–50 29·5 (18·6–38·4)
Standardised mortality ratio for PWID26 7·2–11·3 9·0 (8·1–9·9)
Year that increase in PWID recruitment started10,11 1980–95 1987 (1984–90)
Duration of period of increase in PWID recruitment (years) 1–30 18·4 (13·0–22·4)
Year that decrease in general population transmission started13,14 1994–200013,14 1997 (1995–1998)
Relative risk of HCV transmission in general population after 
decrease
0·01–0·50 0·22 (0·12–0·34)
Relative risk of HCV transmission on OST28 0·40–0·6322 0·52 (0·47–0·57)
Relative risk of PWID HCV transmission risk due to NSP from 
2002†
0·00–1·00 0·26 (0·14–0·42)
Relative risk of PWID HCV transmission risk due to NSP from 2012 0·00–1·00 0·19 (0·10–0·29)
References indicate where prior ranges were obtained from. PWID=people who inject drugs. HCV=hepatitis C virus. 
OST=opioid substitution therapy. NSP=needle and syringe programmes. *All priors were uniformly distributed. 
†NSP have been available since 2001, with a large project for preventing HIV/AIDS beginning in 2002.29,30 
Table 2: Selected parameters used in HCV transmission model for Georgia
No, mild, or moderate liver 
disease
Cirrhosis or decompensated 
cirrhosis
May 1, 2015–Feb 29, 2016
Total number treated 2800* 3779†
Per-protocol SVR 1395/1564 (89·2%) 2245/2960 (75·8%)
Intention to treat SVR 1395/2228 (62·6%) 2245/4346 (51·7%)
Adjusted SVR‡ 1765/2201 (80·2%) 2963/4057 (73·0%)
March, 2016–February, 2019
Total number treated 41 474§ 6259¶
Per-protocol SVR 25 954/26 314 (98·6%) 4497/4665 (96·4%)
Intention-to-treat SVR 25 954/34 024 (76·3%) 4497/6738 (66·7%)
Adjusted SVR‡ 30 104/33 826 (89·0%) 5573/6467 (86·2%)
From May 1, 2015, to Feb 29, 2016, patients were treated with sofosbuvir-based (with or without ribavirin) regimens 
and from March 1, 2016, to Feb 28, 2019,  they were treated with ledipasvir-sofosbuvir combination-based regimens. 
SVR=sustained virological response. *68 patients with no or mild liver disease and 2732 patients with moderate liver 
disease. †3757 patients with cirrhosis and 22 patients  with decompensated cirrhosis. ‡The adjusted SVR assumes 
patients that completed treatment had the per-protocol SVR rate and that 55% of patients lost to follow up during 
treatment were cured on the basis of studies of shorter treatment regimens32 (appendix p 7). §21 608 patients with no 
or mild liver diseases and 19 866 with moderate liver disease. ¶5659 patients with cirrhosis and 601 patients with 
decompensated cirrhosis.
Table 3: Total treatment numbers and SVR rates for Georgia’s hepatitis C elimination programme, by level 
of liver disease
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likely to be treated from March 1, 2019. However, the 
degree to which PWID receive treatment and whether 
individuals with cirrhosis should be preferentially 
treated going forward is uncertain. We, therefore, did 
a sensitivity analysis to assess how the required 
treatment rate to achieve a 90% decrease in prevalence 
by 2020 would change if: individuals with cirrhosis are 
targeted (80% of infected individuals with cirrhosis 
are treated annually); PWID are not treated; or PWID 
are targeted for treatment at twice the rate of other 
groups.
We also did sensitivity analyses to assess how the 
treatment target would change if: the treatment 
programme achieved the upper bound (per protocol) or 
lower bound (intention to treat) sustained virologic 
response rates for all patients; existing needle and 
syringe programmes in Georgia had the effectiveness 
estimated for Europe by a recent Cochrane review (risk 
ratio 9–62% if on needle and syringe programmes);28 
opioid substitution therapy coverage doubled from 2016, 
to 9000 PWID covered in 2019; no peak in PWID 
recruitment occurred; or treatment scale-up was delayed 
for 6 months. Lastly, we used analysis of covariance to 
calculate the variance in the number of treatments 
required to reach elimination that is explained by 
uncertainty in each parameter, for the baseline treatment 
scenario.
All analyses were done with Matlab version R2016b or 
R version 3.5.1.
Role of the funding source
The funders of the study played no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had 
full access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
The Bayesian MCMC-ABC routine produced 554 baseline 
model fits that agreed well with general population and 
PWID demographic and chronic hepatitis C prevalence 
data (appendix pp 17, 18), with considerable uncertainty 
in the PWID population size, reflecting the uncertainty 
in the data described in the Methods. Fits to summary 
statistics and posterior distributions of fitted parameters 
are shown in the appendix (pp 19, 20).
The baseline model fits project that the overall adult 
chronic hepatitis C prevalence and incidence have 
decreased since 2000, with both continuing to decline 
during 2015–20 in the absence of treatment by 11% 
(CrI 2–18; prevalence) and 14% (7–20; incidence; figure 2). 
These decreases imply a reduction in the number of 
new infections each year from 6700 (3542–11 076) to 
5897 (3059–9920) during 2015–20. Conversely, over 
the same period, HCV-related mortality is expected to 
increase by 14% (7–25), from 590 (285–1001) deaths in 
2015, to 676 (344–1091) deaths in 2020.
Projections suggest the PWID population peaked in 
2002 (128 815, CrI 71 855–203 164) but declined to 64 420 
(25 647–121 190) by 2018 (appendix p 21), with the HCV 
incidence among PWID decreasing by 76% (37–95) 
during 2000–05 (figure 2). These parallel decreases 
are required to ensure the model replicates the 
observed ageing among PWID and the decrease in 
HCV infection among young PWID. The HCV 
incidence among PWID decreased further, without 
treatment, from 2·4 new cases (0·19–6·8) per 
100 person-years in 2015, to 2·2 new cases (0·15–8·0) 
in 2020 (figure 2).
Our model projects that the 54 313 treatments delivered 
between May 1, 2015, and Feb 28, 2019, have decreased the 
national prevalence of adult chronic hepatitis C 
by 37% (CrI 30–44), with incidence decreasing similarly 
(37%, 29–44; figure 3). This decrease prevented 
252 (134–389) HCV-related deaths (mortality decrease by 
14%, 3–30) and 3516 (1842–6250) new HCV infections by 
Feb 28, 2019, increasing to 3181 (1992–4393) the number 
of HCV-related deaths and to 20 907 (10 335–37 585) the 
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Figure 2: Chronic hepatitis C prevalence and incidence among adult PWID and the overall adult population 
over time
Data are prevalence (95% CI) or incidence (95% CI). Model projections for current treatment (red line) incorporate 
actual treatment numbers from May 1, 2015, to Feb 28, 2019, and assume a treatment rate of 1000 individuals 
initiating treatment per month continuing from March, 2019. CrI=credible interval. HCV=hepatitis C virus. 
PWID=people who inject drugs. 
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number of HCV infections averted if benefits are tracked 
to 2030.
Assuming all eligible individuals have equal access 
to treatment, continuing current treatment rates 
(1000 individuals initiating treatment per month) will 
halve chronic hepatitis C prevalence (decrease by 51%, 
CrI 42–61, to 2·7%, 1·9–3·5) and incidence (decrease by 
51%, 40–62, to 0·097, 0·046–0·16) by 2020 (figures 3, 4), 
reaching a median 90% reduction in 2026, and mortality 
reaching a 65% reduction in 2028 (appendix p 25).
To reach Georgia’s 90-95-95 treatment target by 2020, 
treatment rate needs to increase to 3361 individuals 
initiating treatment per month from March 1, 2019. This 
scale-up would achieve an 80% (CrI 68–96) reduction in 
prevalence and an 80% (66–96) reduction in incidence of 
chronic hepatitis C by 2020 (figure 4), a median reduction 
of 90% in 2021.
To reach a 90% reduction in prevalence by 2020, a 
monthly treatment rate of 2210 (CrI 1799–4000) 
individuals starting treatment per month would have 
been required over 2015–20. However, with the achieved 
treatment rates to Feb 28, 2019, treatment now needs to 
scale-up to a median of 4144 (2963–5322) individuals 
starting treatment per month from March 1, 2019, to 
reach the 90% reduction in prevalence by 2020. This 
scale-up would decrease HCV incidence by 90% (88–90) 
and chronic hepatitis C related mortality by 31% 
(CrI 18–46) by 2020, with mortality reaching a 
65% reduction by 2025. Variability in the number of 
treatments required for achieving the 90% reduction in 
prevalence by 2020 is mainly due to uncertainty in the 
annual birth rate (35·9% of variation; appendix p 13) and 
parameters related to the transient peak in injection drug 
use initiation (49·0% of variation).
If, instead of equal access to treatment, individuals with 
cirrhosis are preferentially targeted from March 1, 2019 
(80% of cirrhosis patients treated each year), then the 
same treatment rate (4144, CrI 2963–5323, individuals 
starting treatment per month; figure 5) would be needed 
to achieve a 90% reduction in prevalence by 2020 and the 
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same decrease in mortality would occur (31% decrease, 
18–46). If PWID are not treated from March 1, 2019, then a 
90% decrease in prevalence will not be possible because 
current PWID make up a high proportion of prevalent 
infections (13–37%, in 2015). However, it makes little 
difference whether PWID are treated at a higher rate 
or equally to the rest of the population, with both 
scenarios requiring the same treatment rate to achieve a 
90% reduction in prevalence (figure 5; appendix pp 22, 23).
The baseline projections assume an adjusted sustained 
virologic response rate (table 1) and a substantial effect 
of needle and syringe programmes. If, instead, the upper-
bound, per-protocol, sustained virologic response rate is 
assumed, the monthly treatment rate from March 1, 2019, 
reduces to 3579 (CrI 2485–4650) individuals initiating 
treatment per month, whereas it increases to 5167 
(3796–6519) individuals initiating treatment per month if 
the intention-to-treat, sustained virologic response rate is 
used (it assumes that only those not attending the 
sustained virologic response visit are not cured; figure 5). 
The necessary treatment rate only changes marginally if a 
reduced efficacy of needle and syringe programmes28 is 
used (4114, 2938–5734, individuals initiating treatment per 
month) or if opioid substitution therapy coverage is 
doubled (4141, 2952–5316). If no peak in PWID recruitment 
is included, then the required treatment rate increases 
slightly to 4443 (2941–6223) individuals initiating treatment 
per month, but the model no longer fits the calibration 
data well (appendix p 24). Lastly, if treatment scale-up is 
delayed by 6 months to Sept 1, 2019, the required monthly 
treatment rate increases to 5271 (3796–6519) individuals 
initiating treatment per month.
Discussion
Georgia has implemented an ambitious hepatitis C 
elimination programme which aims to reduce the 
prevalence of hepatitis C by 90% by 2020. Hepatitis C 
treatment has been scaled-up considerably since 2015, 
with more than 54 000 HCV-infected individuals treated 
from an estimated 150 000 infected individuals. Our 
model projections suggest this programme has reduced 
hepatitis C prevalence and incidence by 37%, since 2015, 
and will halve prevalence and incidence by 2020. 
However, the current treatment rate (approximately 
1000 individuals initiating treatment per month) needs 
to be quadrupled to achieve the target of reducing 
prevalence by 90% by 2020. Strategies also need to 
maintain high rates of treatment completion, because 
decreased sustained virologic response rates will further 
increase the treatment rate required to reach the 
elimination target. In addition, PWID must be treated. 
Although PWID can be difficult to reach and face 
structural and social barriers to engagement in the 
elimination programme,33 ongoing efforts within the 
programme to decentralise care to harm-reduction 
centres and to follow up patients previously lost to follow-
up are likely to increase treatment among PWID.14
In addition to Georgia’s own elimination goals, WHO 
has set a global target to reduce HCV-related mortality by 
65%. Even if hepatitis C treatment in Georgia is scaled 
up to reach the target of 90% prevalence reduction, it 
will still not meet the WHO mortality target by 2020. 
This result is caused by extensive liver damage among 
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Figure 4: Percent reduction in chronic hepatitis C prevalence (A), incidence (B), and mortality (C) from 2015, 
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Figure 5: Sensitivity analysis of treatment rate needed under alternative model scenarios in comparison with 
baseline model to reach a 90% reduction in chronic hepatitis C prevalence by end of 2020
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currently infected individuals (18% of those who initiated 
treatment had cirrhosis [unpublished data]), which 
limits the short-term mortality benefits of treatment. 
Nevertheless, Georgia is still on track to reach the WHO 
elimination target for mortality (and incidence) by 2030, 
confirming previous modelling projections.34
Importantly, our modelling suggests the prevalence and 
incidence of hepatitis C in Georgia were already in decline 
before the hepatitis C elimination programme began in 
2015 (figure 2). The modelled decline was largely due 
to improvements in harm-reduction measures paired 
with a diminishing PWID population, which reduces the 
contribution of injection drug use to overall transmission. 
Because the epidemic is in decline, it is easier to achieve 
the elimination target, highlighting the important role 
that prevention interventions for PWID can have. In 
the general population, the risk of iatrogenic HCV 
transmission still persists. Developing infection control 
measures to reduce these risks is a key part of the 
elimination programme.35
Case-finding and linkage-to-care initiatives will be 
essential for reaching Georgia’s elimination targets. 
These interventions might be difficult among PWID in 
particular, and although the contribution of PWID to the 
hepatitis C epidemic has declined, they still represent an 
important component of the chronic hepatitis C burden, 
so testing and treatment must be accessible to them. 
Increasing linkage to HCV treatment, in particular for 
PWID through harm-reduction interventions, is a goal 
of the elimination programme.14 HCV treatment at 
harm-reduction sites is being piloted,36 and HCV testing 
at these sites has increased by five times since the start 
of the elimination programme.36 In addition, a pilot 
programme in Tbilisi showed the feasibility of achieving 
high cure rates among PWID.37 Despite these positive 
signs, there are still barriers for PWID linking to care,33 
and there is still uncertainty on the number of PWID 
being treated, because of their non-disclosure of national 
identity numbers required for linking screening and 
treatment data.36 This limits the evaluation of progress 
towards elimination.
This is the first study to evaluate the interim effect and 
treatment targets of an ongoing national-level hepatitis C 
elimination programme by using detailed modelling 
with in-depth data from the programme.38–40 A second 
serosurvey is planned for early 2020s to evaluate if the 
target effect has been achieved, the timing of which will 
be guided by modelling.
The main limitations of our analysis relate to small 
amount of data on how HCV transmission has changed 
over time, in the general population and because of 
injection drug use. Our model suggests a declining 
epidemic in terms of both prevalence and incidence, 
which fits available data (from the 2015 national 
prevalence survey) on reductions in chronic hepatitis C 
prevalence among new PWID over time and young male 
adults having a low chronic hepatitis C prevalence in 
2015. However, the only available comparison of HCV 
prevalence in the general population (from a survey 
done in Tbilisi in 2001–02),41 suggests a stable or 
increasing prevalence of seropositivity (6·7%, 95% CI 
5·7–7·9, in 2001–02 compared with 9·4%, 6·9–12·6, in 
Tbilisi according to the 2015 national survey). The Tbilisi 
survey was not included in our fitting process because of 
uncertainty in its comparability with the 2015 national 
survey, resulting from the clinic-based sampling 
methods used. If the epidemic is increasing as suggested 
by these data, then our projections (data not shown) 
suggest the treatment requirements for elimination will 
be higher than what we estimated (approximately 
5000 individuals initiating treatment per month). 
Additionally, both the 2001–02 study and 2015 national 
survey were household-based surveys and, therefore, did 
not include prisoners or homeless people, potentially 
leading to an underestimation of the burden of chronic 
hepatitis C. It is important that further work evaluate the 
importance of this issue.
HCV-related mortality was not consistently recorded in 
Georgia before 2015, and although this recording is being 
improved as part of the elimination programme, 
complete data were not yet available for this analysis.14 
New data will improve our model calibration. Further-
more, our model assumed a stable population for 
Georgia, despite projections suggesting it might decrease 
(it decreased by 5% during 2010–15).42 This decrease 
should not have an important effect on our projections 
because the changes are quite small.
Data had limitations on many other parameters, 
including being reliant on self-reported data about PWID 
demographics. To account for these limitations, we 
allowed for uncertainty in model parameters while 
remaining consistent with available data. In addition, we 
did sensitivity analyses that made alternative assumptions 
about the effectiveness of needle and syringe programmes 
or the degree to which PWID were treated; and although 
these changes did not affect our elimination projections, 
except if PWID were not treated at all, additional studies 
could still help reduce these uncertainties.
One of the main limitations for translating our results 
into recommendations for the Georgian HCV elimination 
programme is that the model does not incorporate case-
finding, so it cannot identify what screening strategies 
are needed to achieve required rates of chronic hepatitis C 
treatment. In the early stages of the programme, many 
individuals with chronic hepatitis C were already aware 
of their infection and came forward for treatment.9 
General population and targeted screening strategies are 
also underway, with 106 057 positive antibody screening 
tests done in health-care settings, harm-reduction 
services, designated public screening centres, and in 
prisons as of April 2019.34 Other screening and linkage-
to-care strategies are also being piloted or scaled up to 
further increase the identification and treatment of 
undiagnosed infections, including treatment within 
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harm-reduction services, door-to-door and workplace-
based testing, simplification of the treatment pathway to 
encourage retention, and reducing the co-payment for 
patients.14 It is important that these and other possible 
strategies are evaluated to determine the most efficient 
way to achieve elimination,43 which could help other 
countries work toward their own elimination goals.
Georgia has committed to eliminating hepatitis C as a 
public health threat, with the ongoing national 
programme achieving high levels of treatment uptake. 
Data from the programme and our modelling indicate 
an urgent need to improve case-finding, referral, and 
treatment interventions for reaching Georgia’s targets of 
hepatitis C elimination by 2020. Decision makers in 
Georgia will need to evaluate what is feasible for 
achieving hepatitis C elimination. This assessment will 
require considering what is currently limiting treatment 
numbers and how these issues can be remedied. 
Importantly, the treatments already achieved have had 
major effects on HCV transmission in Georgia, and 
even if the elimination targets are not feasible by 2020, 
Georgia will still be one of the first countries to eliminate 
HCV ahead of the WHO target. Lessons learnt from 
Georgia are transferable to other countries that are 
scaling up interventions to prevent hepatitis C.35 In 
particular, our study indicates the importance of identi-
fying the characteristics and dynamics of an epidemic to 
make reliable impact projections.
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